Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Ronit El Hasid
38 years of experience
Clinic is certified :
A tumor marker blood test in Israel typically costs from _diag_93_price_from_ to _diag_93_price_to_. The final price depends on the specific biomarkers tested and the clinic tier. In the US, similar diagnostics cost around $200 on average. Israel offers savings of around 50%. Most tests cover markers like PSA, CA-125, or CEA to monitor cancer activity.
Bookimed Expert Insight: Choosing a large multidisciplinary center like Sourasky Medical Center provides high diagnostic accuracy. This facility treats over 1,800,000 patients annually and maintains a 90% oncology success rate. Patients often find better value by booking tests as part of a formal check-up. These programs typically bundle consultations with top specialists like Dr. Amir Tirosh or Dr. Zohar Dotan. Private clinics like Assuta also offer faster scheduling and greater choice of attending physicians. This speed is vital for patients who need immediate results to start treatment plans.
| Israel | Turkey | Austria | |
| Tumor Marker Blood Test | from $100 | from $100 | from $100 |
No hidden fees – just official clinic prices. Pay at the clinic for Tumor Marker Blood Test upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Tumor Marker Blood Test and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Tumor Marker Blood Test journey.
Dr. Ronit El Hasid leads the Department of Pediatric Oncohematology at Dana Dwek Children's Hospital. She is a specialist in bone marrow and umbilical blood transplantation for children. She has performed over 300 successful transplantations throughout her career. Dr. El Hasid previously practiced at the City of Hope Hospital in Los Angeles.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.